- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.01. | Ipsen's pancreatic cancer drug bests decade-old standard of care | ||
| 20.01. | Disc Medicine pays $10M upfront for monoclonal antibody for rare blood disorder, cancer | ||
| 20.01. | As monotherapy data disappoint, Cyteir lets go of 35 staffers, goes all in on ovarian cancer | ||
| 20.01. | Scoop: Just months after Sanofi AI deal, Atomwise laid off 30% of staffers amid 'strategic shift' | ||
| 20.01. | JPM23 with Robert Nelsen: Our motto is 'do cool s@*t' | ||
| 20.01. | 'Perfect time': SIGA's CEO on retirement; Juvenescence woos GSK vet to lead anti-aging play | ||
| 20.01. | BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial | ||
| 20.01. | Breaking: FDA squashes accelerated hopes for Eli Lilly's Alzheimer's drug as agency asks for more data | ||
| 19.01. | Urovant taps celebrity advocate and patient Holly Robinson Peete for overactive bladder education | ||
| 19.01. | New clinical trial system to soon become mandatory in Europe | ||
| 19.01. | Manufacturing roundup: FDA, Swissmedic ink deal on pharma GMP; SK biotech contracts with Charles River for RNA therapy | ||
| 19.01. | Small-cap CNS outfit inks API deal for preclinical MEK inhibitor | ||
| 19.01. | Intas Pharmaceuticals under FDA scrutiny over 'cascade of failure' in oversight of GMP documents | ||
| 19.01. | In bid to advance manufacturing capabilities, Inscripta buys out two biotechs | ||
| 19.01. | Genentech touts positive Phase III data for Tecentriq/Avastin combo in liver cancer | ||
| 19.01. | Rep. Frank Pallone wants FDA and NIH to act on pharma's noncompliance with trial records law | ||
| 19.01. | After hypertension competitor gets bought, Mineralys lines up IPO plans | ||
| 19.01. | Caris gets $400M loan from OrbiMed and Braidwell; bluebird stock sales brings in $120M | ||
| 19.01. | Amarin, Sarissa continue playing out activist attack | ||
| 19.01. | Off Editas' shelves, iNK cell therapies float to Shoreline | ||
| 19.01. | After hashing out comeback plans, Deciphera looks to raise $125M from stock sale | ||
| 19.01. | By summer solstice, we'll know the fate of Intercept's NASH drug | ||
| 19.01. | Horizon claims mid-stage victory in rare disease, lines up PhIII for new owners at Amgen | ||
| 19.01. | Ipsen has go/no-go decision to make after biotech partner's Parkinson's drug flunks PhIIb | ||
| 19.01. | Don't pack your sunglasses: No plans to move JP Morgan conference, bank says |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
